Abstract
Ferric citrate (FC), a novel oral phosphate binder, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in end-stage renal disease (ESRD) patients receiving dialysis. FC binds to dietary phosphate in the gastrointestinal (GI) tract producing ferric phosphate that is excreted in feces. However, a small quantity of iron is systemically absorbed. There are limited data regarding the safety of the maximum approved dose of FC among peritoneal dialysis (PD) patients. We present a series of 3 PD patients who developed iron overload while receiving FC for management of hyperphosphatemia. These cases highlight the importance of close monitoring of iron studies and question whether a lower maximum dose of FC should be recommended in PD patients. Further studies are needed to assess the safety of the maximum approved dose of FC among PD patients.
Original language | English (US) |
---|---|
Pages (from-to) | 262-266 |
Number of pages | 5 |
Journal | Clinical nephrology |
Volume | 93 |
Issue number | 5 |
DOIs | |
State | Published - May 2020 |
Keywords
- Ferric citrate
- Hyperphosphatemia
- Iron overload
- Peritoneal dialysis
- Phosphate binders
ASJC Scopus subject areas
- Nephrology